Arturo LoAIza-Bonilla, Network Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“RAS(ON) selective inhibitors also changing the landscape for the better.
The figure shows the Objective response rate and disease control rate for zoldonrasib plus mFOLFIRINOX in patients with metastatic PDAC who had not received prior treatment for metastatic disease (European Society for Medical Oncology Gastrointestinal Cancers Congress 2026, Abstract 340O)
Wolpin BM, et al. Safety and efficacy of zoldonrasib (RMC-9805) plus chemotherapy in patients (Pts) with 1L RAS G12D metastatic pancreatic adenocarcinoma (mPDAC). ESMO Gastrointestinal Cancers Congress 2026 – Abstract 340O
N=81 (z plus mFOLFIRINOX, n=41; z plus GnP, n=40)
Median FU: z plus mFOLFIRINOX, 6.1 mo; z plus GnP, 5.7 mo
Efficacy: z plus mFOLFIRINOX (n=22); z plus GnP (n=31)
ORR: 82%; 61%
DCR: 96%; 90%
Grade ≥3 TRAEs: 61% for z plus mFOLFIRINOX; 80% for z plus GnP
Azad NS, et al. Safety and efficacy of zoldonrasib (RMC-9805) plus daraxonrasib (RMC-6236) in patients with 2Lplus KRAS G12D metastatic pancreatic adenocarcinoma (mPDAC). ESMO Gastrointestinal Cancers Congress 2026 – Abstract 341O
N=60 (2L, n=30; ≥3L, n=30)
Median FU: 12.0 mo for 2L; 12.6 mo for ≥3L
Efficacy: 2L; ≥3L:
ORR: 50%; 47%
DCR: 97%; 90%
6-month PFS rate: 71%; 59%
6-month OS rate: 89%; 82%
Discontinuations due to TRAEs: zoldonrasib, n=1; daraxonrasib, n=3.”
Other articles featuring Arturo LoAIza-Bonilla on OncoDaily.